Knowledge Library

Antibody Discovery Platform

WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies, surrogate antibodies, diagnostic antibodies, therapeutic antibodies Antibody drug conjugate services, including site-specific conjugation Related antibody services, including peptide design and recombinant protein production

Resource Type: Brochure
Resource Topic: Antibodies, Antibody Drug Conjugate, Immunology, Oncology

VIEW

T-DXd Resistant Tumor Models with ABCG2

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  One mechanism of resistance involves efflux of the ADC payload by the transporter …Read More >

Resource Type: Presentation
Resource Topic: Antibody Drug Conjugate, Oncology, Tumor Models

VIEW

Pioneering Advanced Modalities in Early Drug Discovery

New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving needs, WuXi Biology has proactively developed a broad range of capabilities, offering integrated solutions to global pharmaceutical and biotech companies for challenging targets. We have established major capabilities for new modalities in the early discovery …Read More >

Resource Type: Article
Resource Topic: Antibody Drug Conjugate, CAR-T Cell, Cell Therapies, DNA-Encoded Library (DEL), Fragment-Based Drug Discovery, Gene Therapies, Oligonucleotides, Oncolytic Viruses, Targeted Protein Degradation

VIEW

Enhertu-Induced Resistant Tumor Models

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  WuXi AppTec offers validated, Enhertu-induced resistant tumor models to support project teams focused …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Antibody Drug Conjugate, Oncology, Tumor Models

VIEW

AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma

In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across a panel of established, in-house diffuse large B-cell lymphoma (DLBCL) patient-derived xenograft (PDX) models. Among our panel of lymphoma PDX models, three represent the germinal center B-cell (GCB) subtype. The authors show that 50% of …Read More >

Resource Type: Poster
Resource Topic: Antibody Drug Conjugate, Lead Optimization, Oncology, Tumor Models

VIEW

OncoWuXi Newsletter November 2022

Resource Type: Newsletter
Resource Topic: Antibodies, Antibody Drug Conjugate, Autoimmune and Inflammatory Diseases, Biomarkers, Cell-based Assays, Cells and Protein Science, Hit-to-Lead, Lead Optimization, Oncology

VIEW

How Does It Work? | Antibody Drug Conjugates

In this week’s installment of our “How Does It Work?” video series, we explore Antibody Drug Conjugates. Monoclonal antibodies are highly versatile molecules that we can modify to generate new and improved cancer therapies. Here we have a type of modified antibody, known as an antibody drug conjugate, or ADC. The ADC contains two antigen …Read More >

Resource Type: Video
Resource Topic: Antibody Drug Conjugate, Biochemical Assays, Cell-based Assays, Oncology, Target Identification and Validation, Target-Specific Assays, Tumor Models

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Resource Type: Brochure
Resource Topic: Antibodies, Antibody Drug Conjugate, Autoimmune and Inflammatory Diseases, Biochemical Assays, Biomarkers, Biophysical Assays, Candidate Selection, CAR-T Cell, Cardiovascular & Metabolic Diseases, Cell Therapies, Cell-based Assays, Cells and Protein Science, Central Nervous System & Pain, Chemical Biology and Proteomics, Dermatology, Discovery Chemistry, DNA-Encoded Library (DEL), DRUG DISCOVERY AND INNOVATION, Fragment-Based Drug Discovery, Gene Therapies, High-throughput screening (HTS), Hit Finding, Hit-to-Lead, Immunology, in silico services, in vitro biology, in vivo Pharmacology, in vivo Toxicology, Infectious Diseases, Lead Optimization, Liver Diseases, Mass Spectrometry-based Assays, Metabolic Diseases, NASH, Oligonucleotides, Oncology, Oncolytic Viruses, Ophthalmology, Phenotypic Assays, Quantum Mechanics, Rare Diseases, Respiratory Diseases, Safety and Early Toxicity, Screening Libraries, Screening Services, Small Molecules, Structural Biology, Target Identification and Validation, Target-Specific Assays, Targeted Protein Degradation, TECHNOLOGY PLATFORMS, THERAPEUTIC AREAS, THERAPEUTIC MODALITIES, Tumor Models

VIEW

Evaluation of the efficacy of ADC in vitro and in vivo

Abstract Antibody drug conjugates (ADCs) are promising complexes with therapeutic potential that aimed to the treatment of solid tumor and hematological malignancies. Compared with the therapeutic monoclonal antibody, an ADC-derived monoclonal antibody is conjugated with cytotoxic agents (payloads) which can deliver potent cellular toxins to targeted cancer cells specifically. We have established a state-of-the-art platform …Read More >

Resource Type: Poster
Resource Topic: Antibody Drug Conjugate, Biochemical Assays, Biomarkers, Cell-based Assays, Immunology, in vitro biology, Lead Optimization, Oncology, Tumor Models

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!